scholarly journals Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study

2021 ◽  
Vol Volume 15 ◽  
pp. 1693-1706
Author(s):  
Ana Filipa Fonseca ◽  
Raquel Lahoz ◽  
Clare Proudfoot ◽  
Stefano Corda ◽  
Emil Loefroth ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Real World ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Patients With Heart Failure ◽  
Male Patients

scholarly journals Association between quality of life and prognosis of candidate patients for heart transplantation: a cross-sectional study

2018 ◽  
Vol 26 (0) ◽  
Author(s):  
Vanessa Silveira Faria ◽  
Ligia Neres Matos ◽  
Liana Amorim Correa Trotte ◽  
Helena Cramer Veiga Rey ◽  
Tereza Cristina Felippe Guimarães
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Heart Transplantation ◽  
Pearson Correlation ◽  
Cross Sectional Study ◽  
Prognostic Scores ◽  
Sectional Study ◽  
Cross Sectional ◽  
Convenience Sample

ABSTRACT Objective: to verify the association between the prognostic scores and the quality of life of candidates for heart transplantation. Method: a descriptive cross-sectional study with a convenience sample of 32 outpatients applying to heart transplantation. The prognosis was rated by the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM); and the quality of life by the Minnesota Living With Heart Failure Questionnaire (MLHFQ) and the Kansas City Cardiomyopathy Questionnaire (KCCQ). The Pearson correlation test was applied. Results: the correlations found between general quality of life scores and prognostic scores were (HFSS/MLHFQ r = 0.21), (SHFM/MLHFQ r = 0.09), (HFSS/KCCQ r = -0.02), (SHFM/KCCQ r = -0.20). Conclusion: the weak correlation between the prognostic and quality of life scores suggests a lack of association between the measures, i.e., worse prognosis does not mean worse quality of life and the same statement is true in the opposite direction.

scholarly journals An international comparison of factors affecting quality of life among patients with congestive heart failure: A cross-sectional study

PLoS ONE ◽  
2020 ◽  
Vol 15 (4) ◽  
pp. e0231346 ◽  
Author(s):  
Brita Roy ◽  
Judith R. L. M. Wolf ◽  
Michelle D. Carlson ◽  
Reinier Akkermans ◽  
Bradley Bart ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Congestive Heart Failure ◽  
International Comparison ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Factors Affecting

Health related quality of life in male patients with osteoporosis: results of a cross sectional study

2012 ◽  
Vol 15 (4) ◽  
pp. 220-226 ◽  
Author(s):  
Karen Voigt ◽  
Stéphanie Taché ◽  
Matthias Hofer ◽  
Carsten Straßberger ◽  
Henna Riemenschneider ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cross Sectional Study ◽  
Health Related Quality ◽  
Sectional Study ◽  
Cross Sectional ◽  
Related Quality ◽  
Health Related ◽  
Male Patients

Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 525-525
Author(s):  
Alberto Dalla Volta ◽  
Francesca Valcamonico ◽  
Carlo Cappelli ◽  
Andrea Delbarba ◽  
Vittorio D. Ferrari ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Cell ◽  
Cell Cancer ◽  
Cross Sectional Study ◽  
Testosterone Replacement ◽  
Sectional Study ◽  
Antiangiogenic Effect ◽  
Cross Sectional ◽  
Male Patients

525 Background: Sunitinib (S) is a standard first line treatment of metastatic renal cell carcinoma (mRCC). Asthenia and fatigue are the most prevalent toxicities but the relevant causes are not fully elucidated. Since endocrine glands are highly vascularized, the potent antiangiogenic effect of S can potentially impair their function. With the exception of hypothyroidism, the endocrine-related side-effects of S have not been extensively explored. Methods: We performed a cross-sectional study in which pituitary, thyroid, parathyroid, adrenal and gonadal functions were assessed in 25 mRCC patients who received 9 months of S therapy. Since a high prevalence of hypogonadism was observed, we subsequently enrolled 16 mRCC male patients in a prospective cohort study in which serum testosterone (T) serum free T, serum FSH and LH were evaluated at baseline and after 6 weeks (1 cycle) of S therapy. In patients eligible for testosterone replacement after andrologic evaluation, a FACT-G questionnaire for quality of life (QoL) assessment was prospectively administered at baseline and after 3 months. Results: In the cross sectional study 15/22 S treated male patients (68%) had serum T below the normal range and 13 of them (87%) presented with low/normal levels of LH. In the prospective study mean T levels (95% CI) were 5.04 ng/ml (3.4 - 6.7) at baseline and 4.1 ng/ml (3 - 5.3) after 6 weeks (p 0.05). The corresponding free T were 91.4 pg/ml (66 – 116.8) and 80.2 pg/ml (65 – 95.3) (p 0.24), respectively. Hypogonadism was observed in 5 (31%) patients at baseline and 10 (63%) patients after 6 weeks of S therapy. In the 5 patients becoming hypogonadic after S therapy, LH was 11.4 mU/ml (3.2 - 19.5) at baseline and 11.5 mUI/ml (0 – 23.5) after 6 weeks. Four patients were addressed to testosterone replacement. QoL significantly improved in 3 of them, with the strongest advantage in the physical comfort area. Conclusions: S therapy induces hypogonadism in a high proportion of male patients with mRCC. Low or inappropriately normal LH levels are consistent with a pituitary origin of the endocrine disorder. Testosterone replacement may improve the QoL and treatment tolerance.

Sign in / Sign up

Export Citation Format

Share Document